Clinical Trials Logo

Basal Ganglia Diseases clinical trials

View clinical trials related to Basal Ganglia Diseases.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06193252 Recruiting - Parkinson Disease Clinical Trials

Slow-SPEED-NL: Slowing Parkinson's Early Through Exercise Dosage-Netherlands

Slow-SPEED-NL
Start date: January 15, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to investigate the feasibility if a remotely administered smartphone app can increase the volume and intensity of physical activity in daily life in patients with isolated Rapid Eye Movement (REM) sleep behaviour disorder over a long period of time (24 months). Participants will be tasked to achieve an incremental increase of daily steps (volume) and amount of minutes exercised at a certain heart rate (intensity) with respect to their own baseline level. Motivation with regards to physical activity will entirely be communicated through the study specific Slow Speed smartphone app. Primary outcomes will be compliance expressed as longitudinal change in digital measures of physical activity (step count) measured using a Fitbit smartwatch. Exploratory outcomes entail retention rate, completeness of remote digital biomarker assessments, digital prodromal motor and non-motor features of PD, blood biomarkers and brain imaging markers. Using these biomarkers, we aim to develop a composite score (prodromal load score) to estimate the total prodromal load. An international exercise study with fellow researchers in the United States and United Kingdom are currently in preparation (Slow-SPEED). Our intention is to analyse overlapping outcomes combined where possible through a meta-analysis plan, to obtain insight on (determinants of) heterogeneity in compliance and possible efficacy across subgroups

NCT ID: NCT05452655 Recruiting - Parkinson Disease Clinical Trials

Intensive Multidisciplinary Rehabilitation and Biomarkers in Parkinson's Disease

Start date: December 9, 2020
Phase: N/A
Study type: Interventional

Parkinson's disease (PD) is a progressive neurological disorder characterized by motor and non-motor symptoms such as rigidity, bradykinesia, resting tremor, cognitive and autonomic dysfunctions, gait and balance difficulties. The impairment of gait, balance and cognitive performances is partially responsive to dopaminergic medications. This emphasizes the importance of non-pharmacological interventions for people with PD (pwPD). Intensive multidisciplinary motor and cognitive rehabilitation has been proposed as a complementary and effective treatment for managing pwPD. Several structural and physiological mechanisms have been suggested to underpin exercise-induced neuroplastic changes in PD, such as enhanced synaptic strength and preservation of dopamine neurons. To date, studies on brain changes induced by motor and cognitive exercises in pwPD have been small-scaled and uncontrolled. Identifying accessible and measurable biomarkers for monitoring the events induced by intensive motor and cognitive rehabilitation program would help in testing the treatment effectiveness and would allow personalization of rehabilitation strategies by predicting patients' responsiveness. Based on validated clinical assessments of intensive multidisciplinary rehabilitation treatment, the project will test the ability of a new set of biomarkers to evaluate rehabilitative outcomes in a cohort of people with PD.

NCT ID: NCT04985539 Recruiting - Parkinson Disease Clinical Trials

The Personalized Parkinson Project de Novo Cohort

PPP-novo
Start date: August 29, 2020
Phase:
Study type: Observational

Currently, the Movement Disorders Society (MDS)-UPDRS scale remains the gold standard to document the outcomes in clinical trials for Parkinson's disease (PD). The MDS-UPDRS is far from infallible, as it is based on subjective scoring (using a rather crude ordinal score), while execution of the tests depends on clinical experience. Not surprisingly, the scale is subject to both significant intra- and inter-rater variability that are sufficiently large to mask an underlying true difference between an effective intervention and placebo. Digital biomarkers may be able to overcome the limitations of the MDS-UPDRS, as they continuously collects real-time data, during the patient's day to day activities. In this study the investigators are interested in developing algorithms to track progression of bradykinesia, gait impairment, postural sway, tremor, physical activity, sleep quality, and autonomic dysfunction (the latter being derived from e.g. skin conductance and changes in heart rate variability).

NCT ID: NCT04871464 Recruiting - Parkinson Disease Clinical Trials

Role and Mechanism of Probiotics in Improving Motor Symptoms in Mild to Moderate Parkinson's Disease

Start date: November 11, 2021
Phase: Phase 4
Study type: Interventional

This study is a multicenter randomized double-blind placebo-controlled study. The research content is 1. The improvement effect of Bifidobacterium triple viable capsules(BIFICO) on motor symptoms and constipation and sleep in mild to moderate Parkinson's disease and the safety of the study; 2. the mechanism of the improvement effect of intestinal microecological changes on motor and constipation symptoms in mild to moderate Parkinson's disease.

NCT ID: NCT04023656 Recruiting - Clinical trials for Paroxysmal Kinesigenic Choreoathetosis

Prognosis of Paroxysmal Kinesigenic Choreoathetosis in Korea

Start date: November 11, 2016
Phase:
Study type: Observational [Patient Registry]

The aim of this study is to assess the prognosis of paroxysmal kinesigenic choreoathetosis (PKC) in Korean.

NCT ID: NCT02696603 Recruiting - Parkinson Disease Clinical Trials

Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower)

mPower
Start date: March 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to understand variation in the symptoms of Parkinson disease. This study uses an iPhone app to record these symptoms through questionnaires and sensors.

NCT ID: NCT01905995 Recruiting - Clinical trials for Basal Ganglia Diseases

Basal Ganglia Local Field Potentials in Gait and Speech

Start date: July 2013
Phase: N/A
Study type: Observational

Electrid activity of the basal ganglia will be recorded with an implantable deep brain stimulation device (supplied by Medtronic Inc). Study hypothesis is that these activities differ according to what the patient does, i.e. are different during gait and speech.